MedTrace Logo

THIO and Cadonilimab in Resectable Hepatocellular Carcinoma

NCT07446257 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-07-07

No results posted yet for this study

Summary

The goal of this clinical study is to find out if cadonilimab or ateganosine plus cadonilimab is effective and safe in treating resectable hepatocellular carcinoma (HCC).

Conditions

  • Resectable Hepatocellular Carcinoma

Interventions

DRUG

ateganosine

ateganosine: 180 mg IV D1, D2, D3 of 21-day cycle

DRUG

Cadonilimab

cadonilimab: 10 mg/kg IV D5 of 21-day cycle

Sponsors & Collaborators

  • Maia Biotechnology

    collaborator INDUSTRY

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Texas Southwestern Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-29
Primary Completion
2029-09-01
Completion
2030-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07446257 on ClinicalTrials.gov